vorasidenib
servier
['vorasidenib', 'indigo']
vorasidenib improved pfs and time-to-next intervention in patients with low-grade idh1/2-mutated #glioma in the phase 3 indigo trial. #asco23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.